Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
The Trump administration on Friday called on Congress to pass its proposed ban on "backdoor deals" that pharmaceutical companies cut with middlemen who get preferred status for their drugs in Medicare's prescription drug plans.
The proposal, unveiled Thursday, would pass an estimated $29 billion in rebates paid to so-called pharmacy benefits managers to consumers. Drug manufacturers pay PBMs the rebates for getting their drugs covered by Medicare's Part D prescription plan. Instead, PBMs would get a flat fee for including drugs on their plans. The rule would also create a new so-called safe harbor for drug discounts to be passed on to patients at the pharmacy counter.
Health and Human Services Secretary Alex Azar also urged Congress to extend the rule to employer-sponsored and other private insurance plans.
"Today's rebate system is set up in the shadows, to serve entrenched interests: drug companies who set these prices so high, and the pharmacy benefit managers who receive billions of dollars in rebates without patients ever knowing where the money goes," Azar said in a statement. "Congress has an opportunity to follow through on their calls for transparency, too, by passing our proposal into law immediately and extending it into the commercial drug market."
Azar, who is scheduled to deliver the remarks at the Bipartisan Policy Center in Washington on Friday, said the Trump administration plans to end "the era of backdoor deals in the drug industry."
Futures prices for shares of the parent companies of the nation's largest PBMs plunged. The nation's four largest PBMs are now all integrated with health insurance firms, following the recent completion of CVS Health's merger with Aetna and Cigna's acquisition of Express Scripts. UnitedHealth Group owns the OptumRX PBM and Anthem will be launching its own unit IngenioRx in the second quarter.
(Chart showing after-hours trading action Thursday)
Cigna's shares were down 5 percent in premarket trading Friday while CVS and UnitedHealth were down 2.6 percent and 1.6 percent, respectively.
The Pharmaceutical Research and Manufacturers of America, or PhRMA, the industry's main trade group, applauded the administration's proposals. The health insurance lobby blasted the proposal, saying the administration "should go back to the drawing board" and take aim directly at high prices set by drugmakers.
Democrats have vowed to lower prescription drug costs as well but have focused on the pharmaceutical industry, which sells their drugs at higher prices in the U.S. than abroad. Spending on prescription drugs in the U.S. increased to $333.4 billion in 2017, according to the latest data from the Centers for Medicare and Medicaid Services.
Earlier this month, House Oversight Committee Chairman Elijah Cummings, D-Md., said he sent letters to 12 drugmakers seeking detailed information and documents about the companies' pricing practices. House Democrats also sent letters to Eli Lilly, Novo Nordisk and Sanofi on Wednesday requesting information on insulin prices and the obstacles to providing more affordable medication.
"For years, drug companies have been aggressively increasing prices on existing drugs and setting higher launch prices for new drugs while recording windfall profits," Cummings said in a statement. The committee's goal is to "determine why drug companies are increasing prices so dramatically, how drug companies are using the proceeds, and what steps can be taken to reduce prescription drug prices."
The proposal, if adopted, would take a while before consumers see a difference. The legislation would have to be debated and passed by both houses of Congress, and federal regulations implementing the rules would likely take months to write.
The proposed rules would apply only to Medicare and Medicaid plans. But senior administration officials say the new rules could ultimately influence the way private sector drug plans are negotiated.